DPM 1001
Alternative Names: DPM-1001Latest Information Update: 09 Jan 2025
At a glance
- Originator Genaera Corporation
- Developer Cold Spring Harbor Laboratory; DepYmed
- Class Amines; Cholanes; Cyclopentanes; Esters; Phenanthrenes; Pyridines; Small molecules
- Mechanism of Action Chelating agents; Protein tyrosine phosphatase non receptor type 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatolenticular degeneration
- Discontinued Breast cancer; Cancer